A national survey of male patients with lupus finds the illness has a significant impact on their physical and emotional health, yet they often do not receive support that could help them cope.
Researchers at Hospital for Special Surgery (HSS) in New York City launched the nationwide survey to assess the needs of male patients and found that 58% reported feeling depressed for several days or more than half the days in the previous two weeks. Regarding support and coping, 52% reported that they received no support. More than 80% of respondents indicated that lupus limited their activities of daily living, mostly due to pain and fatigue.
Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.